Ovid Therapeutics (OVID) EBIT (2016 - 2026)

Ovid Therapeutics (OVID) has reported EBIT for 11 consecutive years, with -$15.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 209.44% year-over-year to -$15.7 million; the trailing twelve-month figure through Jun 2026 stood at -$58.4 million (down 40.39% YoY), and the FY2025 full-year result was -$42.4 million, up 31.42% from the prior year.
• EBIT rose to -$15.7 million in Q2 2026 per OVID's latest filing, from -$17.8 million in the prior quarter.
• Across five years, EBIT topped out at -$5.1 million in Q2 2025 and bottomed at -$20.5 million in Q2 2024.
• Historically, EBIT has averaged -$14.0 million across 5 years, with a median of -$13.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: EBIT surged 75.27% in 2025, then slumped 209.44% in 2026.
• Over 5 years, EBIT stood at -$12.2 million in 2022, then sank by 49.41% to -$18.2 million in 2023, then surged by 41.05% to -$10.7 million in 2024, then slipped by 14.65% to -$12.3 million in 2025, then dropped by 27.7% to -$15.7 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$15.7 million, -$17.8 million, and -$12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.